ExpreS2ion Biotech Holding AB (FRA:5JD0) Total Receivables: €1.15 Mil (As of Mar. 2026)


FRA:5JD0 ExpreS2ion Biotech Holding AB FRA:5JD0
25 GF Score
Price €0.11
GF Value €0.34
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is ExpreS2ion Biotech Holding AB Total Receivables?

ExpreS2ion Biotech Holding AB FRA:5JD0 +5.88% 25 Total Receivables is €1.15 Mil as of Mar. 2026. GuruFocus rates FRA:5JD0 with a GF Score™ of 25/100 and a GF Value™ of €0.34 (Possible Value Trap). The stock has 5 warning signs investors should review.

ExpreS2ion Biotech Holding AB's Total Receivables for the quarter that ended in Mar. 2026 was €1.15 Mil.

ExpreS2ion Biotech Holding AB Total Receivables Related Terms

ExpreS2ion Biotech Holding AB Total Receivables Historical Data

* Premium members only.

The historical data trend for ExpreS2ion Biotech Holding AB's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ExpreS2ion Biotech Holding AB Total Receivables Chart

ExpreS2ion Biotech Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.23 0.21 0.34 0.20

ExpreS2ion Biotech Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.44 0.38 0.20 1.15
FRA:5JD0
25GF Score
ExpreS2ion Biotech Holding AB FRA:5JD0
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ExpreS2ion Biotech Holding AB Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €1.15 Mil mean?
ExpreS2ion Biotech Holding AB (FRA:5JD0) has a Total Receivables of €1.15 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on ExpreS2ion Biotech Holding AB and its competitors.
Is ExpreS2ion Biotech Holding AB's Total Receivables too high?
ExpreS2ion Biotech Holding AB's current Total Receivables is €1.15 Mil. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's Total Receivables compare to VRTX and REGN?
ExpreS2ion Biotech Holding AB's Total Receivables of €1.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on ExpreS2ion Biotech Holding AB and its competitors. ExpreS2ion Biotech Holding AB's current Total Receivables is €1.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB (FRA:5JD0) is currently considered Possible Value Trap. The stock's GF Value™ is €0.34, compared to a current price of €0.11 — trading 68.2% below its estimated fair value. The current Total Receivables is €1.15 Mil. ExpreS2ion Biotech Holding AB's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (FRA:5JD0), the current Total Receivables is €1.15 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ExpreS2ion Biotech Holding AB (FRA:5JD0) Overvalued in 2026?

Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued. The current stock price of €0.11 is trading 68.2% below its estimated GF Value™ of €0.34. GuruFocus considers ExpreS2ion Biotech Holding AB to be Possible Value Trap.

Key valuation signals for FRA:5JD0:

  • Total Receivables: €1.15 Mil
  • GF Value™: €0.34 vs. price of €0.11 (68.2% below fair value)
  • GF Score™: 25/100 with 5 warning signs

No single metric tells the full story. See the FRA:5JD0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ExpreS2ion Biotech Holding AB Business Description

Other Exchanges EXPRS2:Sweden
Address c/o Mindpark, Ronnowsgatan 8c, Helsingborg, SWE, 252 25
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
25GF Score

Get the complete analysis for FRA:5JD0

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.11
Price
€0.34
GF Value